|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5030453A
(en)
|
1983-03-24 |
1991-07-09 |
The Liposome Company, Inc. |
Stable plurilamellar vesicles
|
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US5891467A
(en)
|
1997-01-31 |
1999-04-06 |
Depotech Corporation |
Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
|
|
US6017926A
(en)
|
1997-12-17 |
2000-01-25 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
SK9192000A3
(en)
|
1997-12-17 |
2001-03-12 |
Merck & Co Inc |
Integrin receptor antagonists
|
|
AU776150B2
(en)
|
1999-01-28 |
2004-08-26 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
|
|
WO2000053722A2
(en)
|
1999-03-10 |
2000-09-14 |
Phogen Limited |
Delivery of nucleic acids and proteins to cells
|
|
US6309401B1
(en)
|
1999-04-30 |
2001-10-30 |
Vladimir Redko |
Apparatus and method for percutaneous implant of a paddle style lead
|
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Ｒｎａ干渉の方法とｒｎａ干渉組成物
|
|
US6680068B2
(en)
|
2000-07-06 |
2004-01-20 |
The General Hospital Corporation |
Drug delivery formulations and targeting
|
|
US20080188430A1
(en)
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
|
WO2002100435A1
(en)
|
2001-06-11 |
2002-12-19 |
Centre Hospitalier Universitaire De Montreal |
Compositions and methods for enhancing nucleic acid transfer into cells
|
|
WO2003015757A1
(en)
|
2001-08-16 |
2003-02-27 |
The Trustees Of The University Of Pennsylvania |
Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
|
|
DE10230997A1
(de)
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
EP1658304A4
(en)
|
2002-09-28 |
2009-01-14 |
Massachusetts Inst Technology |
THERAPY ANTIGRIPPALE
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
WO2004048545A2
(en)
|
2002-11-26 |
2004-06-10 |
University Of Massachusetts |
DELIVERY OF siRNAs______________________________________________
|
|
AU2004257373B2
(en)
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
CN1845993B
(zh)
|
2003-08-28 |
2010-06-23 |
诺瓦提斯公司 |
具有平端和3＇修饰的干扰rna双链体
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
CA2566286A1
(en)
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
|
|
EP2990410A1
(en)
|
2004-08-10 |
2016-03-02 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
|
EP1948674A4
(en)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
|
|
ES2556128T3
(es)
|
2006-03-23 |
2016-01-13 |
Roche Innovation Center Copenhagen A/S |
ARN interfiriente pequeño internamente segmentado
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
|
NZ580712A
(en)
|
2007-05-22 |
2011-12-22 |
Marina Biotech Inc |
Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers
|
|
CN101868251B
(zh)
|
2007-08-06 |
2012-10-10 |
千寿制药株式会社 |
含有HIF-1α和HIF-2α表达抑制物质的药物
|
|
US9006191B2
(en)
|
2007-12-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering RNA
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
US8067178B2
(en)
|
2008-03-14 |
2011-11-29 |
Genomic Health, Inc. |
Gene expression markers for prediction of patient response to chemotherapy
|
|
EP3673922A1
(en)
*
|
2008-03-14 |
2020-07-01 |
VisEn Medical, Inc. |
Integrin targeting agents and methods of using same
|
|
WO2009117531A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
|
JP2011516065A
(ja)
*
|
2008-04-04 |
2011-05-26 |
カランド ファーマシューティカルズ， インコーポレイテッド |
Ｅｐａｓ１阻害剤の組成物および使用
|
|
KR20110110776A
(ko)
|
2008-12-18 |
2011-10-07 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2011076807A2
(en)
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
PH12012501596A1
(en)
|
2010-02-24 |
2017-02-03 |
Arrowhead Res Corporation |
Compositions for targeted delivery of sirna
|
|
KR101223660B1
(ko)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
|
|
RU2013117288A
(ru)
|
2010-12-17 |
2015-01-27 |
Эрроухэд Рисерч Корпорейшн |
СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
RU2582235C2
(ru)
|
2010-12-29 |
2016-04-20 |
Ф.Хоффманн-Ля Рош Аг |
Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
|
|
WO2012174224A2
(en)
|
2011-06-17 |
2012-12-20 |
Calando Pharmaceuticals, Inc. |
Methods for administering nucleic acid-based therapeutics
|
|
CA2842039A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
MX2014001965A
(es)
|
2012-04-18 |
2014-03-31 |
Arrowhead Res Corp |
Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
|
|
HK1214301A1
(zh)
|
2013-02-28 |
2016-07-22 |
箭头研究公司 |
治療epas1相關疾病的有機組合物
|
|
US9504747B2
(en)
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
US20160272970A1
(en)
|
2015-03-17 |
2016-09-22 |
Arrowhead Madison Inc. |
RNA Interference Agents
|
|
TWI761305B
(zh)
*
|
2015-05-29 |
2022-04-21 |
美商愛羅海德製藥公司 |
抑制Ｈｉｆ２α基因表現之組合物及方法
|
|
CN120247964A
(zh)
|
2018-02-17 |
2025-07-04 |
箭头药业股份有限公司 |
三炔连接剂和使用方法
|
|
IL309955A
(en)
|
2018-04-27 |
2024-03-01 |
Arrowhead Pharmaceuticals Inc |
Integrin-targeting ligands and their uses
|